The serum Pro-gastrin-releasing peptide, carcinoembryonic antigen and squamous cell carcinoma antigen levels in lung cancer patients with high risk of lung cancer

Abstract

Objective To evaluate the prognostic value of serum Pro gastrin releasing peptide (ProGRP), carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC) in lung cancer patients with high risk of lung cancer. Methods A total of 392 patients treated with Oncology and Respiratory Medicine from January 2011 to December 2015 were enrolled in this study, including 308 cases of non-small cell lung cancer (NSCLC), 84 cases of small cell lung cancer (SCLC) and 116 cases of benign lung tumors.In addition, 144 subjects were enrolled in this study as the healthy group at the same time in Jiaozhou People′s Hospital physical examination center.The diagnostic value of ProGRP, CEA and SCC was analyzed by multivariate Logistic regression model and receiver operating characteristic (ROC) curve, and the serum tumor markers in different stages of lung cancer were compared. Results Compared with the healthy group, ProGRP, CEA, and SCC in the NSCLC group increased significantly, they were (353.2±10.45) ng/L vs (12.87±9.20) ng/L, (3.03±1.79) ng/L vs (1.62±0.08) ng/L, (2.21±0.54) ng/L vs (1.90±0.34) ng/L.The sensitivity, specificity and accuracy of serum ProGRP in the diagnosis of lung cancer were more than 85% and the AUC was 0.940; the sensitivity, specificity and accuracy of serum CEA in lung cancer were 71%, 69% and 69%, AUC=0.926.The sensitivity, specificity, and accuracy of serum SCC in lung cancer were 95%, 55%, and 62%, AUC=0.932. Conclusions ProGRP, CEA and SCC can be used as tumor markers of NSCLC and SCLC, and have a certain correlation with the stage of lung cancer, which can effectively predict the risk of lung cancer in high risk groups of lung cancer. Key words: Carcinoma, non-small-cell lung; Small cell lung cancer; Pro-gastrin-releasing peptide; Carcinoembryonic antigen; Squamous cell carcinoma antigen